Literature DB >> 22493429

Small ubiquitin-like modifier (SUMO) modification mediates function of the inhibitory domains of developmental regulators FOXC1 and FOXC2.

Theodora E Danciu1, Sergey Chupreta, Osvaldo Cruz, Jennifer E Fox, Malcolm Whitman, Jorge A Iñiguez-Lluhí.   

Abstract

FOXC1 and FOXC2 are forkhead transcription factors that play essential roles during development and physiology. Despite their critical role, the mechanisms that regulate the function of these factors remain poorly understood. We have identified conserved motifs within a previously defined N-terminal negative regulatory region of FOXC1/C2 that conforms to the definition of synergy control or SC motifs. Because such motifs inhibit the activity of transcription factors by serving as sites of post-translational modification by small ubiquitin-like modifier (SUMO), we have examined whether FOXC1/C2 are targets of SUMOylation and probed the functional significance of this modification. We find that endogenous FOXC1 forms modified by SUMO2/3 can be detected. Moreover, in cell culture, all three SUMO isoforms are readily conjugated to FOXC1 and FOXC2. The modification can be reconstituted in vitro with purified components and can be reversed in vitro by treatment with the SUMO protease SENP2. SUMOylation of FOXC1 and FOXC2 occurs primarily on one consensus synergy control motif with minor contributions of a second, more degenerate site. Notably, although FOXC1 is also phosphorylated at multiple sites, disruption of sites immediately downstream of the SC motifs does not influence SUMOylation. Consistent with a negative functional role, SUMOylation-deficient mutants displayed higher transcriptional activity when compared with wild type forms despite comparable protein levels and subcellular localization. Thus, the findings demonstrate that SC motifs mediate the inhibitory function of this region by serving as sites for SUMOylation and reveal a novel mechanism for acute and reversible regulation of FOXC1/C2 function.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22493429      PMCID: PMC3365760          DOI: 10.1074/jbc.M112.339424

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  59 in total

1.  SUMO-modified Sp3 represses transcription by provoking local heterochromatic gene silencing.

Authors:  Bastian Stielow; Alexandra Sapetschnig; Christina Wink; Imme Krüger; Guntram Suske
Journal:  EMBO Rep       Date:  2008-07-11       Impact factor: 8.807

Review 2.  SUMOylation and De-SUMOylation: wrestling with life's processes.

Authors:  Edward T H Yeh
Journal:  J Biol Chem       Date:  2008-11-13       Impact factor: 5.157

Review 3.  Axenfeld-Rieger syndrome and spectrum of PITX2 and FOXC1 mutations.

Authors:  Zeynep Tümer; Daniella Bach-Holm
Journal:  Eur J Hum Genet       Date:  2009-06-10       Impact factor: 4.246

Review 4.  The SUMO pathway: emerging mechanisms that shape specificity, conjugation and recognition.

Authors:  Jaclyn R Gareau; Christopher D Lima
Journal:  Nat Rev Mol Cell Biol       Date:  2010-12       Impact factor: 94.444

5.  SUMO-mediated inhibition of glucocorticoid receptor synergistic activity depends on stable assembly at the promoter but not on DAXX.

Authors:  Sam R Holmstrom; Sergey Chupreta; Alex Yick-Lun So; Jorge A Iñiguez-Lluhí
Journal:  Mol Endocrinol       Date:  2008-06-18

6.  Oxidative stress drives disulfide bond formation between basic helix-loop-helix transcription factors.

Authors:  Theodora E Danciu; Malcolm Whitman
Journal:  J Cell Biochem       Date:  2010-02-01       Impact factor: 4.429

Review 7.  Foxc2 transcription factor: a newly described regulator of angiogenesis.

Authors:  Tsutomu Kume
Journal:  Trends Cardiovasc Med       Date:  2008-08       Impact factor: 6.677

8.  SUMOylation inhibits SF-1 activity by reducing CDK7-mediated serine 203 phosphorylation.

Authors:  Wei-Hsiung Yang; Joanne H Heaton; Holly Brevig; Sarmistha Mukherjee; Jorge A Iñiguez-Lluhí; Gary D Hammer
Journal:  Mol Cell Biol       Date:  2008-11-17       Impact factor: 4.272

9.  On the role of FOX transcription factors in adipocyte differentiation and insulin-stimulated glucose uptake.

Authors:  Isabelle Gerin; Guido T Bommer; Martin E Lidell; Anna Cederberg; Sven Enerback; Ormond A Macdougald
Journal:  J Biol Chem       Date:  2009-02-24       Impact factor: 5.157

10.  Active site remodelling accompanies thioester bond formation in the SUMO E1.

Authors:  Shaun K Olsen; Allan D Capili; Xuequan Lu; Derek S Tan; Christopher D Lima
Journal:  Nature       Date:  2010-02-18       Impact factor: 49.962

View more
  13 in total

1.  Phosphorylation regulates FOXC2-mediated transcription in lymphatic endothelial cells.

Authors:  Konstantin I Ivanov; Yan Agalarov; Leena Valmu; Olga Samuilova; Johanna Liebl; Nawal Houhou; Hélène Maby-El Hajjami; Camilla Norrmén; Muriel Jaquet; Naoyuki Miura; Nadine Zangger; Seppo Ylä-Herttuala; Mauro Delorenzi; Tatiana V Petrova
Journal:  Mol Cell Biol       Date:  2013-07-22       Impact factor: 4.272

Review 2.  Forkhead box proteins: tuning forks for transcriptional harmony.

Authors:  Eric W-F Lam; Jan J Brosens; Ana R Gomes; Chuay-Yeng Koo
Journal:  Nat Rev Cancer       Date:  2013-07       Impact factor: 60.716

Review 3.  Oncogenic functions of the FOXC2 transcription factor: a hallmarks of cancer perspective.

Authors:  Kristian M Hargadon; Travis B Goodloe; Nathaniel D Lloyd
Journal:  Cancer Metastasis Rev       Date:  2022-06-14       Impact factor: 9.264

4.  Imbalance between Expression of FOXC2 and Its lncRNA in Lymphedema-Distichiasis Caused by Frameshift Mutations.

Authors:  Sara Missaglia; Daniela Tavian; Sandro Michelini; Paolo Enrico Maltese; Andrea Bonanomi; Matteo Bertelli
Journal:  Genes (Basel)       Date:  2021-04-27       Impact factor: 4.096

5.  Foxc1 and Foxc2 deletion causes abnormal lymphangiogenesis and correlates with ERK hyperactivation.

Authors:  Anees Fatima; Ying Wang; Yutaka Uchida; Pieter Norden; Ting Liu; Austin Culver; William H Dietz; Ford Culver; Meredith Millay; Yoh-Suke Mukouyama; Tsutomu Kume
Journal:  J Clin Invest       Date:  2016-05-23       Impact factor: 14.808

6.  Covalent NEDD8 conjugation increases RCAN1 protein stability and potentiates its inhibitory action on calcineurin.

Authors:  Eun Hye Noh; Hee Sook Hwang; Hee Sun Hwang; Boram Min; Eunju Im; Kwang Chul Chung
Journal:  PLoS One       Date:  2012-10-31       Impact factor: 3.240

7.  Forkhead box protein A2 (FOXA2) protein stability and activity are regulated by sumoylation.

Authors:  Narasimhaswamy S Belaguli; Mao Zhang; F Charles Brunicardi; David H Berger
Journal:  PLoS One       Date:  2012-10-31       Impact factor: 3.240

8.  De-SUMOylation of FOXC2 by SENP3 promotes the epithelial-mesenchymal transition in gastric cancer cells.

Authors:  Yan-hua Ren; Ke-jia Liu; Ming Wang; Ya-nan Yu; Kai Yang; Qin Chen; Bin Yu; Wei Wang; Qi-wei Li; Jian Wang; Zhao-yuan Hou; Jing-yuan Fang; Edward T Yeh; Jie Yang; Jing Yi
Journal:  Oncotarget       Date:  2014-08-30

9.  FOXC2 regulates the G2/M transition of stem cell-rich breast cancer cells and sensitizes them to PLK1 inhibition.

Authors:  Mika Pietilä; Geraldine V Vijay; Rama Soundararajan; Xian Yu; William F Symmans; Nathalie Sphyris; Sendurai A Mani
Journal:  Sci Rep       Date:  2016-04-11       Impact factor: 4.379

10.  SUMOylation modulates FOXK2-mediated paclitaxel sensitivity in breast cancer cells.

Authors:  Gabriela Nestal de Moraes; Zongling Ji; Lavender Y-N Fan; Shang Yao; Stefania Zona; Andrew D Sharrocks; Eric W-F Lam
Journal:  Oncogenesis       Date:  2018-03-13       Impact factor: 7.485

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.